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Fig 2. Urticarial vasculitis in a patient with neuro-
cysticercosis seen on skin biopsy specimen from a new
urticarial papule on the left posterior thigh. Extravasated
erythrocytes (yellow arrow) and a perivascular infiltrate
composed of neutrophils with neutrophilic debris
(black arrows), with some mononuclear cells around the
blood vessels, are consistent with an early leukocytoclastic
vasculitis. (Hematoxylin-eosin stain; original magnifica-
tion: 340.)
Fig 1. Neurocysticercosis in a patient with urticarial
vasculitis: brain magnetic resonance imaging shows a
2.5-cm rim enhancing degenerating cyst (arrow) in the
left frontal lobe.
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response.3 The enzyme-linked immunoelectrotrans-
fer blot of serum (not obtained) is the serologic test
of choice, with higher sensitivity and specificity than
ELISA; however, both tests are unreliable in patients
with 1 degenerating cysticercus (as in our patient) or
calcified granulomas.3
Urticarial vasculitis is an uncommon clinicopath-
ologic entity distinct from acute urticaria based on
dermatopathologic findings of vasculitis. Clinically,
urticarial vasculitis presents with painful pruritus and
erythematous wheals lasting longer than 24 hr,Open access under CC BY-NC-ND license.followed by a residual hyperpigmentation.4 Our
patient’s differential diagnosis also included
Cysticercus cellulosae cutis ( painless subcutaneous
nodules with larval cysts on biopsy)3 and Sweet
syndrome (associated with pyrexia and neutrophilic
infiltrate on histology without evidence of leuk-
ocytoclastic vasculitis).5 However, biopsy results
combined with urticarial lesions on exam solidified
a diagnosis of urticarial vasculitis.
To our knowledge, urticarial vasculitis associated
with T. solium infection in which the urticarial
vasculitis resolved after neurosurgical removal of
the cyst and treatment with albendazole has not been
reported. Physicians should continue to look for
obscure causes of urticarial vasculitis.
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with bevacizumab therapy
To the Editor: We present the case of a 29-year-old
woman with glioblastoma multiforme (GBM) who
Fig 1. Ulceration of corticosteroid-induced striae.
Photograph of ulcerations within abdominal striae in a
patient on bevacizumab for treatment of advanced
glioblastoma multiforme.
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striae.
GBM in the setting of severe headaches and
nausea was diagnosed. After complete resection of
the mass, she was started on a course of dexameth-
asone to which daily temozolomide 75 mg/m2
and every other week bevacizumab 10 mg/kg
were added 4 months later. She also underwent
localized radiation therapy. Soon after starting this
combination regimen, she noted small tender ulcers
on her abdomen and arms.
Physical examination revealed scattered saucer-
shaped ulcerations confined to the striae on her
abdomen and arms (Fig 1). Because bevacizumab-
induced ulceration was suspected and given her
degree of discomfort, bevacizumab was discontin-
ued. The patient remained on temozolomide and
dexamethasone. The ulcers significantly improved
within 1 month with local wound care consisting of
white petrolatum and nonstick dressings.
GBM is the most aggressive primary brain tumor
in adults. Standard treatment for GBM after surgical
resection includes radiotherapy in conjunction with
temozolomide, followed by adjuvant temozolomide
alone. Bevacizumab, a humanized monoclonal
antibody against vascular endothelial growth factor
(VEGF), received FDA approval in 2009 for the
treatment of recurrent GBM.1
Delayed healing of surgical wounds is a well-
known adverse effect of bevacizumab, in addition to
other cutaneous adverse effects including painful
hand-foot syndrome, exfoliative dermatitis, skin
discoloration, and xerosis.2,3 There havebeen several
reports3-5 of ulcer formation within corticosteroid-
induced striae in patients receiving bevacizumab for
advanced GBM. Striae often develop in the setting of
chronic corticosteroid use secondary to epidermal
atrophy and dermal changes from decreased
collagen synthesis. While the exact mechanism ofulceration is unknown, we hypothesize that bevaci-
zumab contributes by impairing striae healing
through VEGF inhibition, rendering them persis-
tently weakened and susceptible to ulceration from
trauma. Additionally, bevacizumab may increase
thrombotic events via endothelial cell disruption,
leading to the formation of vascular microthrombi
and regions of skin necrosis within striae.4 Striae are
vascular in nature, making them more susceptible to
these effects. Once an ulcer forms, bevacizumab
inhibits healing through similar mechanisms.3-5
Proper identification and management is crucial
once a patient presents with ulcerated striae. When
possible, cessation of bevacizumab may lead to
resolution of these areas. However, there are
situations when its withdrawal is not feasible. In
such cases, dermatologists must be aware of the
implications of this regimen and how to prevent
further ulcer formation in susceptible patients. In
patients started on bevacizumab in the setting of
preexisting striae, the striae should be kept
moisturized and protected from trauma.5 Striae
must be closely monitored for ulceration and when
identified, early wound care is key. Several
management techniques have been reported and
include the use of silicone based or colloid dressings
with the addition of silver foam or dressings if signs
of infection are apparent.5 This case reinforces that
ulcers localized to striae are a rare but possible side
effect of combined therapy with dexamethasone and
bevacizumab, and highlights the importance of early
recognition and proper management in these
patients.
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Psoriasis as a manifestation of HIV-related
immune reconstitution inflammatory
syndrome
To the Editor: Immune reconstitution inflammatory
syndrome (IRIS) is a paradoxical exacerbation of a
pre-existing condition or emergence of a previously
unknown disease occurring in an HIV-infected
patient after initiating combined antiretroviral ther-
apy (cART). IRIS begins days to months after starting
cART, and is associated with decreasing viral load.1
The skin accounts for 52% to 78% of presentations,
including a range of infectious, inflammatory, and
neoplastic conditions.2 Inflammatory dermatoses
such as eosinophilic folliculitis, seborrhea, and acne
vulgaris have all been reported.3,4 Here we present,
to our knowledge, the first report of paradoxical
worsening of psoriasis as a presentation of IRIS.
A 63-year-old man with type 2 diabetes mellitus,
hypertension, hepatitis C, HIV diagnosed in 1997,
and a history of mild, untreated less than 1% total
body surface area psoriasis presented to derma-
tology 1 month after starting a new cART, Stribild
(elvitegravir, tenofovir, cobicistat, emtricitabine).
The patient was switched 1 month prior from his
previous cART regimen of Truvada (emtricitabine
and tenofovir disoproxil fumarate), darunavir, and
ritonavir, to Stribild, a once-a-day cART, because
of concerns of medication noncompliance. His
most recent CD4 count, 5 months before presenta-
tion, was 204 cells/L and his viral load was
177,857 copies/mL. Skin examination demonstrated
confluent erythema, edema, and focal areas of
platelike desquamation over the palmar surfaces
of both hands; thick sharply demarcated plaques
with silvery scale over the elbows; and an erythem-
atous patch over the sacrum, with sparing of the
feet and nails, affecting approximately 10% total
body surface area. Despite reports of mild joint
stiffness in his hands, plain film x-rays did notshow signs of psoriatic arthritis. A repeated CD4
count was 138 cell/L and viral load was 257
copies/mL. He met the proposed diagnostic criteria
for IRIS, with worsening of a pre-existing condition
( psoriasis) and a concomitant greater than log 10
reduction in viral load.5 He was started on topical
psoralen plus ultraviolet A light 3 times per week
and clobetasol ointment 0.05% twice daily, with
improvement over the course of 2 months, even-
tually returning to less than 1% affected total body
surface area. Of interest, 1 week before worsening
psoriasis, he also developed herpes zoster
involving the right leg and buttock, which was
resolving at the time of his initial presentation to
dermatology.
At the 12th World AIDS Conference in Geneva
in 1999, French et al6 reported numerous condi-
tions worsening after starting cART and introduced
the term ‘‘immune restoration disease,’’ which is
now more commonly termed ‘‘immune reconstitu-
tion inflammatory syndrome.’’ Over 15 years after
the first reports, IRIS remains a well-described
but poorly understood phenomenon. There is
emerging evidence that one of the immunopatho-
genic mechanisms of IRIS involves the rapid
and dysregulated shift from the T helper (Th)2-
predominant state of advanced HIV infection to
the Th1- and Th17-dominant state of immune
recovery. It is intriguing that psoriasis, a Th1- and
Th17-mediated inflammatory condition, has not, to
our knowledge, until now been reported to
undergo an IRIS reaction, despite being a relatively
common HIV-associated dermatosis.
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